Citations 44

A Phase 3 Trial of Brepocitinib in Dermatomyositis

New England Journal of Medicine | March 28, 2026 | Volume: 394 | Issue: 19 | Pages: 1883-1893

10.1056/nejmoa2503531 | PMID 41910335

Fatal Cardiomyopathy Secondary to Seronegative Immune-Mediated Necrotizing Myopathy: A Case Report

American Journal of Case Reports | February 12, 2026 | Volume: 27 | Issue: No issue available | Pages: No page available

10.12659/ajcr.951603 | PMID 41834235

GG-06 Single cell gene expression studies in lupus patient monocytes reveal novel patterns reflecting disease activity, interferon, and medical treatment

Genetics, Genomics and Epigenetics | May 14, 2024 | Volume: No volume available | Issue: No issue available | Pages: A30.1-A30

10.1136/lupus-2016-000179.58

Collaborative research in myositis-related disorders: MIHRA, a global shared community model

Clinical and Experimental Rheumatology | March 4, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55563/clinexprheumatol/hc1lsf | PMID 38436382

Development and Implementation of a Quality Improvement Strategy for Obtaining Muscle Biopsies Utilizing DMAIC Methodology (P4.272)

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.p4.272

Development and Implementation of a Quality Improvement Strategy for Obtaining Muscle Biopsies Utilizing DMAIC Methodology (I8-2.003)

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.i8-2.003

Increased Mortality and Higher Frequency of Hematologic Malignancies in Inclusion Body Myositis: A Population-Based Case-Control Study (2542)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.2542

A 40-year population-based epidemiologic study of sporadic inclusion body myositis (sIBM) in Olmsted County, Minnesota (1739)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1739

Anti-cN1A Antibodies do not Help Characterize sIBM (1256)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1256

Disease spectrum of myopathies with elevated aldolase and normal creatine kinase

European Journal of Neurology | November 3, 2023 | Volume: 31 | Issue: 2 | Pages: No page available

10.1111/ene.16117 | PMID 37922500

Abstract Background and purpose Elevation of serum creatine kinase (CK) or hyperCKemia is considered a biological marker of myopathies. However, selective elevation of serum aldolase with normal CK has been reported in a few myopathies, including dermatomyositis, immune‐mediated myopathy with perimysial pathology and fasciitis with associated myopathy. The aim was to investigate the disease spectrum of myopathies with isolated aldolase elevation. Methods Medical records were reviewed to identify patients >18 years old seen between December 1994 and June 2020 who had pathologically proven myopathies with elevated aldolase and normal CK level. Patients with alternative causes of aldolase elevation were excluded. Results Thirty‐four patients with various types of myopathies were identified. Myopathies were treatable in 27 patients. The three most common etiologies were dermatomyositis ( n = 8), overlap myositis ( n = 4) and nonspecific myopathy ( n = 4). Perimysial pathology comprising inflammation, fragmentation, vasculitis, calcified perimysial vessels or extracellular amyloid deposition was found in 17/34 patients (50%). Eight dermatomyositis patients with selective elevated aldolase were compared to 24 sex‐ and age‐matched patients with dermatomyositis and hyperCKemia. Dermatomyositis patients with normal CK significantly ( p < 0.05) had less frequent cutaneous involvement (50.0% vs. 100.0%) and fibrillation potentials (50.0% vs. 90.5%) but higher median erythrocyte sedimentation rate (33.5 vs. 13.5 mm/h) and more common perifascicular mitochondrial pathology (37.5% vs. 4.2%). Conclusion Isolated aldolase elevation can be found in a greater variety of myopathies than initially thought and most were treatable. Dermatomyositis is the most common myopathy with selective elevation of aldolase in our cohort, which features some unique characteristics compared to dermatomyositis with hyperCKemia.